Observation of GPI-anchored protein-deficient (PNH-Type) cells In Japanese patients with bone MArrow failure syndrome and in those suspected of having PNH
Not Applicable
- Conditions
- BMF syndrome (AA, MDS, PNH)
- Registration Number
- JPRN-UMIN000019227
- Lead Sponsor
- Japan PNH Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2956
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with malignancies requiring 2.Patients considered inappropriate to participate in the study 3.Patients who has been registered with this study 4.Patients who have used Eculizumab within at the informed consents
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients showing PNH-type granulocytes and erythrocytes greater than or equal to 1% at the first FCM analysis
- Secondary Outcome Measures
Name Time Method 1.Proportion of patients showing PNH-type granulocytes greater than or equal to 0.003% and erythrocytes greater than or equal to 0.005% identified at the first FCM analysis 2.Changes in percentage of PNH-type cells in the patients who were found to be positive at the first FCM analysis (granulocytes greater than or equal to 0.003% and erythrocytes greater than or equal to 0.005%) 3.Relationship between response to IST made after the PNH-type cell analysis and increase or decrease of PNH-type cells